DKSH Holding AG AI Stock Analysis
Want to see CH:DKSH full AI Analyst Report?
DKSH Holding AG (DKSH) AI Stock Analysis
DKSH Holding AG
(Six Swiss:DKSH)
The score is driven mainly by stable but low-margin financials with reliable (though sometimes volatile) cash generation, supported by a constructive earnings outlook and strong recent cash conversion. Technicals are positive but appear somewhat overextended, while valuation is only moderately attractive given a ~21x P/E despite a healthy ~3.5% dividend.
DKSH Holding AG (DKSH) vs. iShares MSCI Switzerland ETF (EWL)
- Market Cap
- CHF 5.11B
- Dividend Yield
- 3.18%
- Average Volume (3M)
- 79.22K
- Price to Earnings (P/E)
- 23.3
- Beta (1Y)
- 0.90
- Revenue Growth
- -1.37%
- EPS Growth
- 8.55%
- Country
- Switzerland
- Employees
- 24,942
- Sector
- General
- Sector Strength
- 55
- Industry
- Consulting Services
DKSH Holding AG Business Overview & Revenue Model
Company Description
DKSH Holding AG provides various market expansion services in Thailand, Greater China, Malaysia, Singapore, rest of the Asia Pacific, and internationally. The company offers sourcing, market insights, marketing, sales, e-Commerce, distribution, logis...
How the Company Makes Money
DKSH makes money primarily by providing market expansion services to client companies and earning fees and margins tied to the sale and distribution of those clients’ products across Asian markets. Key revenue streams typically include: (1) Distribut...
DKSH Holding AG Earnings Call Summary
Overall the call conveyed a constructive and confident view: the company delivered its strongest first‑half top‑line growth in three years, double‑digit EPS growth, excellent cash generation and progress across strategic priorities (M&A, AI, sustainability). Challenges highlighted were primarily translational FX headwinds and temporary margin pressure from deliberate investments and ramp‑ups (healthcare, AI and marketing). Management reiterated confidence in a stronger second half, a robust M&A pipeline, and medium‑term margin expansion.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
DKSH guided that Core EBIT for 2026 is expected to be higher than in 2025, while flagging a moderately negative translational FX impact for the full year if exchange rates remain broadly unchanged; management expects acquisitions announced/completed to date to add roughly +1 percentage point to 2026 net sales, foresees capex of ~0.3–0.4% of net sales and a tax rate of 27–29%, is targeting a modest Core EBIT margin improvement (around +10 bps), expects a double‑digit full‑year profit contribution from associates (data‑center projects) by year‑end, and reiterated confidence in stronger H2 momentum driven by AI, data‑center growth and accelerated M&A—supported by strong cash generation (H1 free cash flow CHF 147.7m; cash conversion 130.8%).
DKSH Holding AG Financial Statement Overview
Summary
Mid-range fundamentals: income statement stability but thin margins (net ~1.6–2.0%, operating ~2.3–3.1%) and limited growth, with a notable 2025 revenue/FCF drop flagged as a key uncertainty. Balance sheet is solid with manageable leverage (debt-to-equity ~0.32–0.58) and consistent ROE (~9–12%), though leverage has trended higher. Cash flow is reliably positive (OCF ~CHF 322–393M; FCF ~CHF 237–341M) with decent earnings conversion, but FCF growth has been volatile (including sharp weakness in 2025).
Income Statement
56NeutralBalance Sheet
62PositiveCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.02B | 11.07B | 11.09B | 11.07B | 11.32B | 11.11B |
| Gross Profit | 661.90M | 746.90M | 1.64B | 1.65B | 792.80M | 770.50M |
| EBITDA | 420.90M | 438.30M | 472.00M | 434.90M | 437.30M | 460.60M |
| Net Income | 212.20M | 202.90M | 214.80M | 182.00M | 201.10M | 223.90M |
Balance Sheet | ||||||
| Total Assets | 5.55B | 5.50B | 5.85B | 5.47B | 5.88B | 5.35B |
| Cash, Cash Equivalents and Short-Term Investments | 503.70M | 538.40M | 609.10M | 687.20M | 636.40M | 673.70M |
| Total Debt | 762.50M | 753.00M | 839.80M | 958.20M | 1.01B | 587.10M |
| Total Liabilities | 3.78B | 3.68B | 3.97B | 3.73B | 4.05B | 3.46B |
| Stockholders Equity | 1.71B | 1.76B | 1.82B | 1.69B | 1.76B | 1.81B |
Cash Flow | ||||||
| Free Cash Flow | 308.60M | 281.90M | 321.30M | 340.80M | 237.00M | 338.20M |
| Operating Cash Flow | 339.30M | 320.10M | 362.90M | 393.10M | 321.90M | 393.20M |
| Investing Cash Flow | -106.30M | -99.70M | -75.60M | -116.50M | -511.80M | -147.90M |
| Financing Cash Flow | -209.20M | -267.60M | -364.20M | -185.20M | 180.70M | -239.50M |
DKSH Holding AG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:DKSH, the sentiment is Positive. The current price of 78.60 is above the 20-day moving average (MA) of 77.28, above the 50-day MA of 72.00, and above the 200-day MA of 64.33, indicating a bullish trend. The MACD of 1.86 indicates Positive momentum. The RSI at 70.88 is Negative, neither overbought nor oversold. The STOCH value of 85.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:DKSH.
DKSH Holding AG Peers Comparison
Overall Rating
CH:BELL71.5Outperform
CH:GALE70Outperform
CH:KARN70Outperform
CH:KNIN66.3Neutral
CH:DKSH62Neutral
CH:SIGN62Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | CHF 1.66B | 20.87 | 4.90% | 2.65% | 1.67% | -36.08% | |
| 70Outperform | CHF 4.55B | 28.65 | ― | 2.74% | 6.48% | -17.25% | |
| 70Outperform | CHF 1.86B | 72.00 | ― | 2.48% | 2.60% | -65.24% | |
| 66Neutral | CHF 27.84B | 28.55 | ― | 2.56% | 1.09% | -5.24% | |
| 62Neutral | CHF 5.11B | 23.25 | ― | 3.18% | -1.37% | 8.55% | |
| 62Neutral | CHF 5.89B | -151.71 | -1.59% | ― | -4.89% | -122.68% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CH:DKSH | DKSH Holding | 78.60 | 26.49 | 50.82% | |
| CH:KNIN | Kuehne + Nagel | 234.40 | 87.60 | 59.67% | |
| CH:KARN | Kardex AG | 241.50 | -19.76 | -7.56% | |
| CH:BELL | Bell Food Group | 264.00 | 45.46 | 20.80% | |
| CH:SIGN | SIG Group AG | 15.42 | 6.65 | 75.83% | |
| CH:GALE | Galenica AG | 91.40 | 6.82 | 8.06% |
DKSH Holding AG Corporate Events
DKSH Advances Women’s Health Equity Through Global Patient Initiative
DKSH Business Unit Healthcare is an integrated healthcare commercialization and distribution partner serving Asia Pacific and other international markets. Its services cover pharmaceuticals, consumer health products, medical devices, market expansion...
DKSH Ranks 21st Among Southeast Asia’s Best Workplaces
DKSH, a market expansion services provider for companies seeking growth in Asia and beyond, ranked 21st in Fortune’s 2026 list of the 100 Best Companies to Work For in Southeast Asia. The recognition marks its second consecutive appearance and highli...
DKSH Secures CHF 100 Million Sustainability-Linked Loan
DKSH is a Market Expansion Services provider serving companies across Asia Pacific, Europe, and North America through its Healthcare, Consumer Goods, Performance Materials, and Technology businesses. It supports clients with sourcing, market insights...
DKSH Buys Global Rights to Roche’s Rocephin to Bolster Healthcare Own Brands
DKSH has acquired from Roche the rights to Rocephin, a broad-spectrum antibiotic whose active ingredient ceftriaxone is on the World Health Organization’s Model List of Essential Medicines, across more than 80 markets in Asia Pacific, Europe, Africa,...
DKSH Buys NewBridge to Build Middle East Healthcare Platform
DKSH has agreed to acquire 100% of Dubai-headquartered NewBridge Pharmaceuticals for an enterprise value of USD 390 million, establishing a healthcare commercialization platform in the Middle East and North Africa. The deal extends DKSH Healthcare’s...
DKSH Expands Grünenthal Pain Management Partnership Across Eight Asia-Pacific Markets
DKSH’s Healthcare unit has expanded its collaboration with Grünenthal, a global leader in pain management, to commercialize four specialty pain medicines across up to eight Asia-Pacific markets. The agreement builds on an existing relationship and un...
DKSH to Bolster Southeast Asia Pharma Footprint with Acquisition of Thailand’s P.R. Chemicals
DKSH Performance Materials has signed an agreement to acquire Thailand-based P.R. Chemicals, a long-established distributor of Active Pharmaceutical Ingredients serving more than 100 pharmaceutical customers across diverse therapeutic areas. Founded...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 17, 2026
